CRISPR THERAPEUTICS AG (CRSP) /
The cash flow of CRISPR THERAPEUTICS AG over the past 10 years
Chart CRISPR THERAPEUTICS AG: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, CRISPR THERAPEUTICS AG's operating cash flow was -$345.01M and its capital expenditures $914K, leaving free cash flow of -$345.93M. Free cash flow was above zero in 2 of the 10 years shown. It ranged from -$532.93M in fiscal 2022 to $457.27M in fiscal 2021. Capital expenditures were highest in fiscal 2021, at $81.7M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$345.01M | $914K | -$345.93M |
| 2024ended Dec 31, 2024 | -$142.77M | $1.9M | -$144.68M |
| 2023ended Dec 31, 2023 | -$260.38M | $9.47M | -$269.85M |
| 2022ended Dec 31, 2022 | -$495.74M | $37.19M | -$532.93M |
| 2021ended Dec 31, 2021 | $538.97M | $81.7M | $457.27M |
| 2020ended Dec 31, 2020 | -$238.37M | $18.36M | -$256.72M |
| 2019ended Dec 31, 2019 | $56.68M | $6.68M | $49.99M |
| 2018ended Dec 31, 2018 | -$96.24M | $2.77M | -$99.01M |
| 2017ended Dec 31, 2017 | -$70.09M | $7.81M | -$77.91M |
| 2016ended Dec 31, 2016 | -$52.86M | $3.02M | -$55.88M |
Fiscal years as CRISPR THERAPEUTICS AG reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on CRISPR THERAPEUTICS AG
- The revenue of CRISPR THERAPEUTICS AG
- The profitability of CRISPR THERAPEUTICS AG
- The debt of CRISPR THERAPEUTICS AG
- All of CRISPR THERAPEUTICS AG's financials, charted
Companies of a similar size
- CUZCOUSINS PROPERTIES INC
- CIGIColliers International Group Inc.
- RYNRAYONIER INC.
- MATMATTEL INC /DE/
- NWENORTHWESTERN ENERGY GROUP, INC.
Not investment advice. This page shows what CRISPR THERAPEUTICS AG filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.